SK Bioscience Co. Ltd.

01/14/2022 | Press release | Distributed by Public on 01/14/2022 01:51

Material Business Matters Related to Investment Decisions (Acquisition of Domestic Product License for Novavax COVID-19 Vaccine)

Material Business Matters Related to Investment Decisions
1. Title Acquisition of Domestic Product License for Novavax COVID-19 Vaccine
2. Details 1. Product name
- NUVAXOVID Pre-filled Syringe (SARS-CoV-2 Spike Protein Vaccine(Recombinant))

2. Target disease
- Prevention for SARS-CoV-2

3. Date of license application(approval) of product and licensing authority
- Application date : 2021.11.15
- Approval date : 2022.01.12
- Approval authority : Ministry of Food and Drug Safety (MFDS, Republic of Korea)

4. Expected effect
- Recombinant SARS-CoV-2 antigen protein contained in this vaccine forms the antibodies against the SARS-CoV-2 virus inside the body and exhibits an immune response when exposed to the SARS-CoV-2, enabling prevention against COVID-19.

5. Future plans
- Expected for domestic supply
3. Date of board resolution (decision date) or confirmation date 2022-01-12
- Attendance of outside directors Present(No.) -
Absent(No.) -
- Attendance of auditors (members of Audit Committee who are not outside directors) -
4. Other matters to be factored into investment decisions
- The above product's codename is 'NVX-CoV2373'.

- The above '3. Date of board resolution(decision date) or confirmation date' is the date of the approval.
※ Related disclosure -